格隆汇2月27日丨康希诺生物(06185.HK)发布2024年度业绩快报公告,报告期内,集团实现营业收入人民币8.46亿元,同比增加137.01%;实现归属于母公司所有者的净亏损人民币3.79亿元,同比亏损减少74.45%;实现归属于母公司所有者的扣除非经常性损益的净亏损人民币4.41亿元,同比亏损减少72.61%。报告期内,集团工作重点主要为推进流脑结合疫苗的商业化进程及非新冠疫苗产品的研发。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.